Chemoprvention traials in the cervix: Design, feasibility, and recruitment

Journal of Cellular Biochemistry

Volumn 59, Issue 23 S, 1995, Pages 104-112

  Mitchell, Michele Follen ^a   Hittelman, Walter N ^a   Laton, Reuben ^a   Nishioka, Kenji ^a   Tortolero‐Luna, Guillermo ^a   Richards‐Kortum, Rebecca ^b   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

cervical intraepithelial neoplasia; Chemoprevention; fluorescence spectroscopy; squamous intraepithelial lesion

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CAROTENE; BIOLOGICAL MARKER; CYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; ORNITHINE DECARBOXYLASE; PROTEIN P53; RAS PROTEIN; RETINOIC ACID RECEPTOR; RETINOID; SPERMIDINE; SPERMINE;

CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; HUMAN; METHODOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; UTERINE CERVIX TUMOR; VAGINA SMEAR; CANCER CONTROL; CANCER RESEARCH; CONFERENCE PAPER; FLUORESCENCE SPECTROSCOPY; HIGH RISK PATIENT; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ANTICARCINOGENIC AGENTS; COLPOSCOPY; FEASIBILITY STUDIES; FEMALE; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS TYPES;

EID: 0029443274     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240590914     Document Type: Article

References (43)

1. Chemoprevntion of cancer
2. Surrogate endpoint biomarkers for Phase II cancer chemopervention trials
3. The chemoprevention of cancer: Directions for the future
4. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review
5. Approaches to the development and marketing approval of drugs that prevent cancer
6. Progress in applied chemopreventive research
7. Chemoprevention clinical trials
8. Interim Guidelines for the management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop
9. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
10. Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy
11. The natural history of intraepithelial neoplasia: Relevance to the search if intermediate endpoint biomarkers
12. Devleopment of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: Relationships to fundamental properties of preinvasive (intraepithelial) neoplasia
13. Cervical intraepithelial neoplasia and condyloma
14. Obeservations on the biology of cervical dysplasia
15. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses
16. The accuracy of colposcopy
17. The natural history of cervical intraepithelial neoplasis
18. HPV and cervical neoplasia: Review of case‐control and cohort studies
19. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
20. Role of epidemiology in defining events that influence transmission and natural history of anogenital papillomavirus infection
21. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenitial types
22. Human papillomavirus infection and other risk factors for cervical neoplasia: A case‐control stydy
23. A cohort study of the risk for cervical intraepithelial neoplasia grade 2 or 3 in realation to papillomavirus infection
24. Chemoprevention of cervix cancer: Phase I‐II: A feasibility study involving the topical vaginal administration of retinyl acetate gel
25. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial
26. Folate deficiency and cervical dysplasia
27. Evaluation of topically applied trans‐retinoic acid in the treatment of cervical intraepithelial lesions
28. A Phase I trial of beta‐all‐transretinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia
29. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all‐trans‐retinoic acid: A randomized trial
30. A Phase I trial of topically applied trans‐retinoic acid in cervical dysplasia—clinical efficacy
31. Chemoprevention of cervical cancer with folic acid: A Phase III southwest oncology group intergroup study
32. Cervical dysplasia regression induced by all‐trans‐retinoic acid
33. Quality control in image cytometry: DNA ploidy
34. Nuclear texture: Can it be used as surrogate endpoint biomarker?
35. Study of the fluorescence properties of normal and neoplastic human cervical tissue
36. Fluorescence spectroscopy: A diagnostic tool for cervical intraepithelial neoplasia (CIN)
37. In vivo diagnosis of cervical intraepithelial neoplasia using 337 nm‐excited laser‐induced fluorescence
38. In vivo fluorescence spectroscopy: Potential for non‐invasive, automated diagnosis of cervical intraepithelial neoplasia and use as a surrogate endpoint biomarker